Intellia Therapeutics named Jing L. Marantz as EVP and chief medical officer, effective Oct. 26. Marantz, former CMO of Scholar Rock, brings rare disease approval experience as the company nears commercialization of its first CRISPR gene editing product and advances Phase 3 trials in transthyretin amyloidosis.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
